前沿速览006期| CAR-T治B淋 前沿览新知
01
继发中枢神经系统淋巴瘤患者CAR-T细胞治疗结局报告：一项多中心队列研究
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
第一作者：Epperla N
J Hematol Oncol (IF=28.5). 2023 Nov 9;16(1):111.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/37946255/
02
CD19 CAR-T细胞治疗复发/难治性非霍奇金淋巴瘤中的放疗桥接、巩固与挽救：多中心专家共识
Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach
第一作者：Saifi O
Am J Hematol (IF=12.8). 2023 Nov 11.
全文网址：https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.27155
03
CD19 CAR-T细胞的单细胞图谱
A single-cell atlas of CD19 chimeric antigen receptor T cells
第一作者：Li X
Cancer Cell (IF=50.3). 2023 Nov 13;41(11):1835-1837.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S1535-6108(23)00316-1
04
CAR-HEMATOTOX评分可识别经Brexu-cel治疗后血液学毒性、感染和预后不良的高风险R/R MCL患者
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
第一作者：Rejeski K
Am J Hematol (IF=12.8). 2023 Nov;98(11):1699-1710.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/ajh.27056
05
非霍奇金淋巴瘤CAR-T治疗30天后具有氟代脱氧葡萄糖活性残留病灶的巩固性放疗
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
第一作者：Saifi O
Haematologica (IF=10.1). 2023 Nov 1;108(11):2982-2992.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620596/
06
复发/难治性大B细胞淋巴瘤患者CAR-T治疗后进展的挽救性放疗
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
第一作者：Ababneh HS
Haematologica (IF=10.1). 2023 Nov 1;108(11):2972-2981.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620597/
07
CD19 CAR-T细胞治疗后18F-FDG PET/CT评估残留病灶或淋巴瘤复发的炎症反应
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy
第一作者：de Boer JW
Blood Adv (IF=7.5). 2023 Nov 14;7(21):6710-6716.
全文网址：https://ashpublications.org/bloodadvances/article/7/21/6710/497690/Inflammatory-reactions-mimic-residual-or-recurrent
08
Defibrotide预防性治疗CAR-T细胞治疗相关神经毒性综合征：一项Ⅱ期临床试验
A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrom
第一作者：Jacobson CA
Blood Adv (IF=7.5). 2023 Nov 14;7(21):6790-6799.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023009961/496695/A-phase-2-trial-of-defibrotide-for-the-prevention
09
抗CD30 CAR-T细胞治疗CD30+淋巴瘤的弱应答和强毒性：Ⅰ期临床试验结果
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase I trial
第一作者：Brudno JN
Blood Adv (IF=7.5). 2023 Nov 8:bloodadvances.2023011470.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011470/498655/Transient-responses-and-significant-toxicities-of
10
通过电活性纳米注射技术高效工程化制备CAR-T细胞
Engineering Efficient CAR-T Cells via Electroactive Nanoinjection
第一作者：Shokouhi AR
Adv Mater (IF=29.4). 2023 Nov;35(44):e2304122.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/adma.202304122
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2023.11-17 valid until 2025.11
供稿与审核：临床开发与医学部